Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. The drug, an apoptosis signal-regulating ...

While it was too early to plan for late-stage trials, Skovronsky argued, "I think having a positive Phase II trial here with really meaningful data and NASH obligates us to think about next steps ...